Bgm Group Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bgm Group Ltd (BGM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bgm Group Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 38M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+154.4% annualized vs trailing 12 months).
- Scale: Bgm Group Ltd ranks #456 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Bgm Group Ltd accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BGM Sales vs. its Competitors, Q4 2024
Bgm Group Ltd generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -47.3% for Bgm Group Ltd. Bgm Group Ltd's share of combined industry revenue moved from 0.01% to 0.00%, a gain of 0.00 percentage points.
Bgm Group Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bgm Group Ltd | No | Yes | Yes | Yes |
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BGM Stock Performance relative to its Competitors
BGM Stock Performance relative to Similar-Size Competitors
BGM Stock Performance relative to Similar Growth & Profitability Competitors
Bgm Group Ltd's Comment on Competition and Industry Peers
Bgm Group Ltd's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Hunan Jianlang Pharmaceutical Co., Ltd. | Named by the company | 85% |
| Hainan Pharmaceutical Factory Co., Ltd. No. 2 Pharmaceutical Factory | Named by the company | 85% |
| Shanxi Datong Tongxing Antibiotics Co., Ltd. | Named by the company | 85% |
| Anhui Fengyuan Pharmaceutical Co., Ltd. | Named by the company | 85% |
| Jiangxi Pharmaceutical Co., Ltd. | Named by the company | 85% |
| Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. | Named by the company | 85% |
| Yunnan Baiyao Group Co., Ltd. | Named by the company | 85% |
| Chifeng Pharmaceutical Co., Ltd. | Named by the company | 85% |
| Kunming Pharmaceutical Group Co., Ltd. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Bgm Group Ltd's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Bgm Group Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Bgm Group Ltd | Diversified Pharmaceutical and Allied Products 62.22 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).